Acuitas, Partner CureVac Settle Clash Over Vaccine-Tech Patents

Acuitas Therapeutics Inc. and CureVac NV have settled their clash over who controls patents central to a blockbuster Covid-19 shot, according to filings in Virginia federal court.

Vancouver-based Acuitas sued CureVac, its German collaborator, last November seeking to have four Acuitas scientists—including a co-founder—added as inventors to four of 10 patents that CureVac alleges are infringed by BioNTech SE and Pfizer Inc.'s Comirnaty vaccine. Acuitas and CureVac filed a notice of settlement Thursday in the US District Court for the Eastern District of Virginia.

• Acuitas and Curevac also filed a notice of settlement Thursday in another case, in which ...